Rakovina Therapeutics Inc. is a biopharmaceutical company focused on developing cancer treatments targeting DNA-damage response mechanisms. The company faces significant concerns with a low financial health score of 43, highlighted by a negative return on equity (ROE) of -90.7% and return on assets (ROA) of -44.5%, indicating poor profitability. However, it maintains a reasonable current ratio of 1.28, suggesting adequate short-term liquidity. The market cap of $4.15M and stock price of $0.17 reflect investor caution, potentially due to the lack of revenue generation and high operational risks in the biotech sector.
Loading financial metrics...
Company has $1.9M in cash but burned $1.1M last quarter. At this burn rate, only 1.8 quarters of runway remain without additional financing.
Company posted a loss of $-5.1M over the last year, representing Infinity% of revenue.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)